These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Diffuse-Type Tenosynovial Giant Cell Tumor of the Knee with Concurrent Polymicrobial Infection ( Marshall JH; Skedros JG; Campana CF; Seibert AM Case Rep Infect Dis; 2021; 2021():5523212. PubMed ID: 34557317 [TBL] [Abstract][Full Text] [Related]
27. Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled. Barile A; Sabatini M; Iannessi F; Di Cesare E; Splendiani A; Calvisi V; Masciocchi C Radiol Med; 2004 Apr; 107(4):356-66. PubMed ID: 15103287 [TBL] [Abstract][Full Text] [Related]
29. MR imaging findings for differentiating nonhemophilic hemosiderotic synovitis from diffuse-type tenosynovial giant cell tumor of the knee. Ando T; Kato H; Kawaguchi M; Nagano A; Hyodo F; Matsuo M Jpn J Radiol; 2021 Jan; 39(1):76-83. PubMed ID: 32860160 [TBL] [Abstract][Full Text] [Related]
30. Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study. Spierenburg G; Staals EL; Palmerini E; Randall RL; Thorpe SW; Wunder JS; Ferguson PC; Verspoor FGM; Houdek MT; Bernthal NM; Schreuder BHWB; Gelderblom H; van de Sande MAJ; van der Heijden L Eur J Surg Oncol; 2024 Feb; 50(2):107953. PubMed ID: 38215550 [TBL] [Abstract][Full Text] [Related]
31. Localized pigmented villonodular synovitis of the knee: a report of two cases. Chien YL; Chiang C; Lee CH; Lin LC; Au MK Zhonghua Yi Xue Za Zhi (Taipei); 1996 Dec; 58(6):448-52. PubMed ID: 9068214 [TBL] [Abstract][Full Text] [Related]
32. Management of tenosynovial giant cell tumour of the foot and ankle. Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469 [TBL] [Abstract][Full Text] [Related]
35. A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis. Bernthal NM; Healey JH; Palmerini E; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Burke ZD; Geiger EJ; Spierenburg G; Laeis P; Beyerlein E; Ye X; van de Sande M J Surg Oncol; 2022 Dec; 126(8):1520-1532. PubMed ID: 36006054 [TBL] [Abstract][Full Text] [Related]
36. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). Tap W Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241 [TBL] [Abstract][Full Text] [Related]
37. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Blay JY; El Sayadi H; Thiesse P; Garret J; Ray-Coquard I Ann Oncol; 2008 Apr; 19(4):821-2. PubMed ID: 18296418 [No Abstract] [Full Text] [Related]
38. Pigmented villonodular bursitis/diffuse giant cell tumor of the pes anserine bursa: a report of two cases and review of literature. Maheshwari AV; Muro-Cacho CA; Pitcher JD Knee; 2007 Oct; 14(5):402-7. PubMed ID: 17669658 [TBL] [Abstract][Full Text] [Related]
39. Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis). Bertoni F; Unni KK; Beabout JW; Sim FH Am J Surg Pathol; 1997 Feb; 21(2):153-63. PubMed ID: 9042281 [TBL] [Abstract][Full Text] [Related]